Loading...
Loading...
HRMY| Name | Value |
|---|---|
| Revenues | 134.2M |
| Cost of Revenue | 25.0M |
| Gross Profit | 109.2M |
| Operating Expense | 62.3M |
| Operating I/L | 46.9M |
| Other Income/Expense | -2.8M |
| Interest Income | 3.4M |
| Pretax | 44.1M |
| Income Tax Expense | 9.8M |
| Net Income/Loss | 34.3M |
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company in the United States. It specializes in developing and commercializing therapies for patients with rare neurological disorders. The company's primary product, WAKIX, is a medication designed to address excessive daytime sleepiness in adult patients with narcolepsy. By focusing on this niche market, Harmony Biosciences generates revenue through the sale of WAKIX and related pharmaceutical products, catering to the specific needs of individuals with narcolepsy and contributing to the company's overall financial success.
